{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-22-000012","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2022-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.650811+00:00","generated_at":"2026-06-26T13:56:27.108215+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LianBio reports Q4 net loss $21.2M; cash $403.2M; mavacamten Phase 3 ongoing","bullets":["Net loss $21.2M in Q4 2021 vs $12.7M Q4 2020; full-year loss $196.3M vs $139.6M.","Cash, equivalents, marketable securities $403.2M at Dec 31, 2021; runway through 2023.","Phase 3 EXPLORER-CN trial of mavacamten initiated in Chinese oHCM patients; Breakthrough Therapy designation granted.","Infigratinib approved under named patient program for cholangiocarcinoma in Hainan pilot zone.","Three programs (TP-03, NBTXR3, infigratinib) expected to enter Phase 3 in China by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-22-000012","json":"https://secwatch.observer/filing/0001831283-22-000012.json","markdown":"https://secwatch.observer/filing/0001831283-22-000012.md","text":"https://secwatch.observer/filing/0001831283-22-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000012/0001831283-22-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000012/lian-20220330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T13:56:27.108215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}